Supergen (SUPG) Announces Sale of Select Non-Core Assets to Intas
More News related to SUPG
- SuperGen Inc. (SUPG) MP-470 Demonstrates Clinical Benefit in Lung Cancer Patients
- SuperGen (SUPG) Announces Departure of Chief Medical Officer
- SuperGen (SUPG) Announces Departure of Chief Medical Officer
- After-Hours Movers 4/27: PRXL, MSPD, ININ, AAN Higher; X, RCII, SONO, HBI Lower
- SuperGen (SUPG) Reports Strong Q1 Earnings; Guides FY09
More News related to Mergers and Acquisitions
- Oclaro (OCLR) Closes Deal with Newport (NEWP) to Exchange Strategic Assets
- Elron Electronic (ELRN) to Negotiate with Clal Industries and DIC Related to Elron's 15% Interest in NetVision
- Bemis Co (BMS) Acquires Alcan Packaging Food Americas Business From Rio Tinto's (RTP) for $1.2B
- Covanta (CVA) Agrees to Acquire Veolia (VE) Environmental Services North Amreica
- EMC Corp (EMC) Raises Offer For Data Domain (DDUP) to $33.50/Share
SuperGen Inc. (Nasdaq: SUPG) has signed a definitive agreement to sell the rights to anticancer agents mitomycin and paclitaxel to Intas Pharmaceuticals Ltd. for $1.2 million.
SuperGen will receive $600,000 shortly after signing with the balance due at the time of product transfer later this quarter. SuperGen will also sell for additional consideration certain related inventory with the transaction. Both products were part of SuperGen's initial corporate strategy to move into the commercial oncology market through generic products and then transition into propriety markets as products were approved. Additional non-core assets may be divested later this year.
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
